BP-1-102 is a potent and selective STAT3 inhibitor. STAT3 is a cytoplasmic transcription factor that induces the expression of genes related to tumorigenesis. BP 1-102 exhibits antitumor activity against Waldenstrom macroglobulinemia, a rare form of B cell non-Hodgkin lymphoma.